主要研究方向为淋巴瘤和多发性骨髓瘤等淋巴组织肿瘤的诊断和治疗，研究着重致力于提升慢性淋巴细胞白血病、滤泡淋巴瘤、套细胞淋巴瘤、华式巨球蛋白血症、边缘区淋巴瘤、毛细胞白血病、弥漫大B细胞淋巴瘤等B细胞淋巴瘤患者的生活质量和生存时间。

1.Shuhua Yi*, Yuting Yan*, et al Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022 Feb 1;132(3):e153283. IF= 15.9

2.Yuting Yan, et al. Determination of MYD88 and CXCR4 mutation for clinical detection and their significance in Waldenström macroglobulinemia. Clin Cancer Res. 2024 Oct 7. IF= 10.0

3. Gang An*, Yuting Yan*, et al. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia, 2020 Feb;34(2):578-588. IF= 11.4

4.Shuhua Yi*, Yuting Yan*, et al. High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic Leukemia. Leukemia, 2021 Aug;35(8):2412-2415. IF= 11.4

5.Yuting Yan, et al. Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China. Front Immunol. 2023 Jul 7;14:1184395. IF=7.3

6. Yuting Yan, et al. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH. Blood Adv. 2022 Jan 25;6(2):441-451. IF= 7.5

7. Yuting Yan, et al. The impact of response kinetics following initial therapy for multiple myeloma in the era of novel agents. Blood Advances, 2019 Oct 8;3(19):2895-2904. IF= 7.5

8. Wang Jun*, Yuting Yan*, et al. Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM. Blood Adv. 2022 Jul 12;6(13):4049-4059. IF= 7.5

9. Yuting Yan, et al. Subtype distribution, clinical features and survival in B-cell chronic lymphoproliferative disorders in China: a review of 1592 cases. Clin Lymphoma Myeloma Leuk. 2020 Jun;20(6):e270-e283. IF= 2.7

10.Shuhua Yi*, Yuting Yan*, et al. Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region, Oncotarget. 2017 Oct 19;8(58):98757-98770. IF= 5.3